LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LeMaitre Vascular reports solid Q4 performance and eyes growth

LeMaitre Vascular's Q4 2022 performance showed growth in sales and income, with strong guidance for 2023.
Despite challenges with gross margin and product line issues, the company is well-positioned for future growth.
Opportunities lie in M&A, sales force expansion, and improving operational efficiency.
Strategic investments have bolstered the company's ability to meet demand and regulatory requirements.

LeMaitre Vascular reports robust Q1 sales and eyes Asia expansion

LeMaitre Vascular delivered strong sales and operating income in Q1 2023, driven by pricing strategies and market expansion efforts.
While facing challenges like rising expenses and competitor risks, the company aims to maintain profitability and drive growth through strategic initiatives.
Opportunities in Asia Pacific expansion and the Aziyo distribution agreement offer avenues for revenue growth and margin improvement.
Overall, LeMaitre's focus on maintaining margins, exploring new markets, and product innovation positions it for continued success in 2023.

LeMaitre Vascular reports robust Q2 sales growth and eyes international expansion

LeMaitre Vascular's Q2 performance reflects strong sales growth, pricing power, and operational efficiency, positioning the company for future success.
While facing margin challenges, the company's diversified product portfolio, international expansion plans, and solid cash position present growth opportunities.
Strategic focus on addressing challenges, optimizing operations, and capitalizing on growth opportunities will be crucial for sustained success and market leadership.

LeMaitre Vascular excels in Q3, eyes growth opportunities ahead

LeMaitre Vascular's Q3 performance was strong, with growth in sales and margins.
The company faces challenges in international markets and sales and marketing dynamics.
Opportunities lie in pricing strategies, product focus, and upcoming product filings.
Overall, LeMaitre Vascular is well-positioned for growth and strategic acquisitions.

LeMaitre Vascular posts strong Q4 results, eyes global expansion opportunities

LeMaitre Vascular's strong performance in Q4 2023 showcases robust sales growth and margin improvement.
While facing challenges such as ongoing impacts from the pandemic and tax rate assumptions, the company is well-positioned for growth.
Strategic initiatives like sales force expansion, APAC expansion, and M&A activities align with opportunities for market penetration and revenue growth.
Guidance for 2024 indicates a focus on operational efficiency and growth strategies to drive continued success.

LeMaitre Vascular excels in Q1 2024, eyes European expansion

Overall, LeMaitre Vascular's Q1 performance showcases strong financial growth, operational improvements, and strategic positioning for future success. The company's focus on expanding its market presence and product approvals sets a positive outlook for continued growth and profitability.

LeMaitre Vascular (LMAT) reports strong Q3 performance and eyes APAC growth

LeMaitre Vascular (LMAT) demonstrated robust sales growth, operational strength, and strategic focus in Q3 2024, positioning itself for continued success. Challenges include pricing strategies and leadership transition, while opportunities exist in sales expansion, regulatory milestones, and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AdaptHealth Corp

AHCO vs. LMAT: Which Stock Is the Better Value Option?

AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?

BURLINGTON, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 24th Annual Needham Virtual Growth Conference on Friday, January 14, 2022, at 3:30 PM.

LeMaitre to Present at the Needham Virtual Growth Conference

LeMaitre Vascular is a small-cap medical devices maker with the potential to continue growing rapidly in the years ahead.

Why You Should Consider Buying This Little-Known Medical Devices Stock

BURLINGTON, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming virtual investor conferences.

LeMaitre to Participate at Upcoming Investor Conferences

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.09% and -2.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Lags Q3 Earnings and Revenue Estimates

LeMaitre Vascular (NASDAQ:LMAT) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Recap: LeMaitre Vascular Q3 Earnings

BURLINGTON, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

LeMaitre Q3 2021 Financial Results

BURLINGTON, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2021 financial results on Thursday, October 28, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Third Quarter 2021 Earnings Results on October 28, 2021

Descartes Systems Group

Alphabet

Old Dominion Freight Line

West Pharmaceutical Services

In light of increasing market volatility, five stocks with high business quality and have outperformed the Standard & Poor's 500 index in the year to date are Alphabet Inc. ( GOOGL , Financial)( GOOG , Financial), Old Dominion Freight Line ( ODFL , Financial), West Pharmaceutical Services Inc. ( WST , Financial), The Descartes Systems Group Inc. ( DSGX , Financial) and LeMaitre Vascular Inc. ( LMAT , Financial) according to the High Quality Low CapEx Screener, a Premium screen nested within GuruFocus' All-in-One Screener.

5 High-Quality Stocks Outperforming the S&P 500

BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four virtual investor conferences in September.

LeMaitre Vascular to Participate at Upcoming Investor Conferences in September

LeMaitre Vascular's operating fundamentals and balance sheet suggest it's a buy, depending on your objectives.

Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2021 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 17.65% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Beats Q2 Earnings Estimates

BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q2 2021 results, announced an $0.11/share quarterly dividend and provided guidance.

LeMaitre Q2 2021 Financial Results

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "

BURLINGTON, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Second Quarter 2021 Earnings Results on July 29, 2021

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings Growth

LeMaitre Vascular Inc (NASDAQ: LMAT) has announced preliminary Q2 2021 results and sees net sales of $40.7 million compared to an estimated $37.9 million, up 64%Y/Y on a reported basis and +35% organically. It expects gross margin in the range of 65.5% to 66.1%, -2.7% at the midpoint vs.

LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% Discount

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of $54.50 per share. Gross proceeds to LeMaitre from the offering are expected to be approximately $54.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by LeMaitre. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 150,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

LeMaitre Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by LeMaitre. In addition, LeMaitre intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

LeMaitre Vascular Announces Proposed Public Offering of Common Stock

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021.

LeMaitre Provides Q2 2021 Update

Did LeMaitre Vascular jeopardize its payout with its recent 16% dividend lift?

Should Investors Consider This Expanding Healthcare Business After Its Massive Dividend Hike?

BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Goldman Sachs 42nd Annual Virtual Global Healthcare Conference on Thursday, June 10, 2021, at 5:30 PM ET.

LeMaitre to Present at the Goldman Sachs Virtual Global Healthcare Conference

BURLINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it received CE marks under the European Medical Devices Directive (93/42/EC as amended by 2007/47/EC) for the following five products. Marks for the five products had previously lapsed due to a change in notified bodies.

News for LeMaitre Vascular Stock (LMAT)